Pharmacy Act 2010

Registration of premises as pharmacies. The Act makes registration of premises the primary legal vehicle for authorising pharmacy businesses. The Board must grant registration unless s 43 grounds for refusal apply (s 39(1)). Registration is in the name of the applicant (s 39(2)), is for a period prescribed by regulation and renewable (s 45), and is evidenced by a certificate of registration (s 51(1)-(2)). The register must record address, registered person and conditions (s 49(2)), and the Board must notify the CEO under the Medicines and Poisons Act of information recorded in the register (s 51A).

Pharmacy business and practice of pharmacy. “Pharmacy business” has a defined statutory meaning: a commercial business consisting of the provision of pharmaceutical services, excluding some public hospitals and certain permit holders under the Medicines and Poisons Act (s 3). “Practice of pharmacy” is defined to include compounding, dispensing and advising on medicines (s 3). The Act separates the premises registration task (licensing of physical premises) from the professional regulation and registration of pharmacists, which remains with the Health Practitioner Regulation National Law (WA) (s 3 definition of pharmacist).

Who may own and limits. Ownership and proprietary interests are tightly constrained. A person may only own a pharmacy business if they are a pharmacist, a partnership where each partner is a pharmacist or close family member of a pharmacist, a pharmacist controlled company, a friendly society, or the preserved company (s 54(1)). The Act places numerical limits on ownership: a pharmacist or friendly society may not own interests in more than four pharmacies (s 55(1)-(2)); the preserved company is limited to one (s 55(3)); close family members of a pharmacist are limited to interests in up to four pharmacies (s 55(4)). New friendly societies face an acquisition ceiling (s 55(5)-(6)). Proprietary interest is broadly framed to capture arrangements prescribed by regulation or franchise‑style profit‑sharing (s 3(2)).

Pharmacist responsibility and supervision. If the registered owner is a pharmacist, that pharmacist has overall responsibility for the pharmacy business (s 56(1)). If not, the owner must appoint a pharmacist to have overall responsibility (s 56(2)), and notify the Board within seven days (s 56(3)). The pharmacy business must be carried on under the personal supervision of a pharmacist at all times (s 57). Failure to meet these obligations attracts fines (ss 56-57).

Standards, conditions and inspections. Minimum standards of fitness for premises are left to the regulations (s 62(2)(a)) and the Board may inspect registered pharmacies during business hours to ensure compliance (s 44). The Board may impose conditions on registration at grant or later (s 47), may cancel or refuse renewal where standards are not met (s 46) but may, if satisfied it is in the public interest, register or continue registration despite non‑compliance subject to conditions (s 48).

Enforcement and remedies. The Board may cancel or refuse renewal (s 46), impose conditions (s 47), and require surrender of certificates on cancellation (s 65). Criminal and civil penalties are set for a range of contraventions (see Part 7 and Penalties and enforcement section below). The Act provides for review by the State Administrative Tribunal (s 68) and for prosecution of offences in a magistrate’s court (s 70).

Regulatory architecture and governance. The Board is a small statutory body: four members appointed by the Minister, three pharmacists and one consumer representative (s 5). It has corporate status (s 4(2)) and procedural rules around meetings, conflicts of interest, delegation, committees and a registrar (ss 10, 13-31). The Minister may give general directions (s 11), but not in relation to particular persons or matters (s 11(2)); the Minister has statutory access to Board information subject to identity protections (s 12). Rules can be made by the Board but require Governor confirmation (s 61(3)); regulations are made by the Governor and can override inconsistent rules (s 62(3)).

Transitional and special entities. The Act preserves certain institutional arrangements in the transitional provisions: the “preserved company” (St John of God Health Care Incorporated) is treated specially (s 3 definition and ss 40-41), the unincorporated Pharmaceutical Society is taken to be incorporated (s 88) and the new Board continues the legal personality of the former Council in relation to corporate matters (s 79).

Key technical definitions should be noted: “pharmacist” is the health professional registered under the Health Practitioner Regulation National Law (WA) (s 3), “pharmacy business” excludes public hospitals and certain permit holders (s 3), “proprietary interest” has a broad statutory reach and is extended by regulations (s 3(2)), and “supermarket” is explicitly defined and feeds into prohibitions on locating pharmacies wholly or partly within supermarkets (s 3; see ss 43(e), 46(1)(e)).

Primary regulated persons. The Act directly affects owners and operators of pharmacy businesses and the pharmacists who work in them. Ownership rules (s 54) restrict proprietorship to pharmacists, pharmacist partnerships, pharmacist controlled companies, friendly societies and the preserved company. Persons who currently hold proprietary interests but are not within these categories must re‑structure to comply or divest. Those intending to acquire or dispose of proprietary interests must notify the registrar 14 days before the change (s 52), a prospective compliance cost and timing constraint.

Registered premises and their staff. Pharmacies must be registered premises (Part 4). The proprietor in whose name the premises are registered must ensure overall responsibility and supervision by a pharmacist (ss 56-57), and provide reasonable assistance to inspectors (s 44(2)). Staff and professional pharmacists face obligations to ensure supervision and may be affected by conditions the Board imposes on registration (s 47).

Consumers and public health agencies. The Act affects consumers indirectly by enabling the Board and the Department to maintain information on registered pharmacies in a public register (ss 49-51) and by creating mechanisms to ensure minimum standards at premises (s 62(2)(a)). The Board must notify the CEO under the Medicines and Poisons Act of information recorded in the register (s 51A), creating a channel to medicines regulators.

Investors, companies and market participants. The Act constrains market structures. Corporates seeking to hold pharmacy interests must fit within the defined categories, notably “pharmacist controlled company” (s 3) or “friendly society” (s 3). Corporates that are not structured to meet those definitions cannot lawfully hold proprietary interests in pharmacy businesses (s 54). There are caps on the number of pharmacies an eligible owner may hold (s 55), and a statutory bar on premises that are wholly or partly in supermarkets (s 43(e), 46(1)(e)), which will affect commercial site selection and diversification strategies.

Professional regulators and government. The Health Practitioner Regulation National Law (WA) remains the source of pharmacist registration (s 3). The Board interfaces with the Minister (ss 11-12), and the Minister has rights to information (s 12) and may give directions (s 11), though not in relation to particular persons or proceedings (s 11(2)). The Act also places specific transitional duties on government officials and agencies (Part 9) and exempts transactions occurring under the transitional provisions from state taxes (s 91).

Third parties and suppliers. Entities that supply goods or services to pharmacies or that enter commercial arrangements with them must be aware that the statutory concept of “proprietary interest” captures certain franchise or profit‑sharing arrangements (s 3(2)(b)-(c)). Those who contract with a pharmacy should consider whether their arrangements confer rights tied to profits because that may amount to a proprietary interest for the purposes of the Act.

Legal and compliance advisers. Lawyers, accountants and compliance officers representing pharmacies, pharmacists, investors or potential acquirers will need to advise on the registration process (s 42), grounds for refusal (s 43), notification obligations (s 52), limits on ownership (s 55), and the administrative process for cancellation, conditions and review (ss 46-48, 67-68). The Act sets criminal penalties for false or misleading information in applications or compliance documents (s 64), elevating the importance of accurate declarations.

Wider stakeholders. The incorporated Pharmaceutical Society, the preserved company, friendly societies, and the National Board/National Agency are engaged through transitional arrangements (Part 9) and through information‑sharing (s 51A), so the Act affects professional bodies and public health administration beyond individual pharmacies.

Duties of the Board and Minister. The Board must administer registration, monitor and enforce compliance (s 8). It has broad powers necessary to perform its functions (s 9), may delegate powers in writing to Board members, committees or the registrar (s 10), and must furnish annual reports and data specified in s 38. The Minister may give written directions after consulting the Board (s 11(1)), but may not direct in respect of a particular person, application or proceeding (s 11(2)). Directions must be tabled in Parliament within 14 sitting days and included in the Board’s annual report (s 11(3)).

Duties of applicants and registered proprietors. Applicants must apply in the approved form, pay application fees where prescribed and supply information required by regulations (s 42(1)). They must comply with requests for information and facility inspections (ss 42(2)-(4)). A person intending to acquire or dispose of ownership or a proprietary interest must give 14 days’ written notice to the registrar (s 52). The registered proprietor must ensure the pharmacy business is carried on at registered premises (s 53) and ensure personal supervision by a pharmacist at all times (s 57).

Duties relating to pharmacist responsibility. The person in whose name a pharmacy is registered who is not a pharmacist must appoint a pharmacist to have overall responsibility within the statutory process (s 56(2)). That appointment must be notified to the Board within seven days with specified details and evidence of consent (s 56(3)). A pharmacy cannot operate without a pharmacist appointed to have overall responsibility (s 56(4)).

Rights to registration and requirements for refusal or cancellation. The Board must grant applications unless s 43 grounds exist (s 39(1)). Grounds for refusal include failure to meet minimum standards as prescribed by regulation, false or misleading information, non‑compliance with Board requests, breach of ownership rules (s 43(a)-(d)) and the supermarket location criteria (s 43(e)). The Board must cancel or refuse renewal in similar circumstances (s 46(1)). However, the Board may impose conditions at grant or later (s 47) and may register premises or continue registration despite non‑compliance where it is satisfied it is in the public interest and imposes conditions (s 48).

Procedural rights and review. Before cancellation or non‑renewal, the Board must give notice and reasons and provide 14 days to make written representations (s 46(2)-(3)). The Board must provide written reasons for decisions refusing registration, cancelling or imposing conditions and give notice within 30 days (s 67(2)). A person aggrieved by those decisions may apply to the State Administrative Tribunal for review (s 68).

Inspection and enforcement rights. The Board may enter and inspect registered pharmacies during business hours to ensure compliance with minimum standards (s 44(1)). Pharmacists and registered proprietors must provide reasonable assistance (s 44(2)). The Board may require surrender of certificates of registration on cancellation (s 65), and legal proceedings for offences may be brought in the Board’s name by the registrar or an authorised person (s 70(1)).

Rights concerning public register and privacy. The Board must keep an accurate register and make it available for public inspection (s 49(1); s 50). The register must include address, name of registrant and conditions (s 49(2)). Notwithstanding that openness, the register need not include all information and may not disclose private addresses without consent (s 50(5)).

Conflicts of interest and disclosure duties. Board members and committee members must disclose material personal interests as soon as the facts come to knowledge and record the disclosure in minutes (s 25). Failure attracts a fine of $10,000 (s 25(1) penalty). Disqualified members must not vote or be present while the matter is considered (s 26), subject to the Board passing a resolution that the section is inapplicable (s 27) or the Minister declaring sections 26 and 28 inapplicable for a specified matter (s 29).

Duty not to misuse information and protections for Board actions. Members or former members must not make improper use of information to gain advantage; the contravention attracts a $5,000 fine (s 32). The Act protects persons acting in good faith in the performance or purported performance of functions under the Act from tort liability and removes state liability for such acts (s 66).

Rulemaking and regulatory standards. The Board may make rules (s 61) but rules have no effect until confirmed by the Governor (s 61(3)). The Governor may make regulations including on minimum standards for premises, prohibitions on combined businesses, and fees (s 62(2)). Where a regulation conflicts with a rule the regulation prevails (s 62(3)).

Financial duties and reporting. The Board must keep proper accounts, prepare financial statements in accordance with Australian Accounting Standards and have annual audits (ss 36-37). The Board funds consist of fees, state grants and other lawful receipts (s 35). Annual reporting obligations with specified data (s 38) place disclosure duties on the Board.

Range and hierarchy of penalties. The Act combines administrative decisions (registration, conditions, cancellation) with civil fines, and a high‑level criminal provision for false or misleading information. Fines are specified in many sections and vary depending on whether the offender is an individual or a body corporate. The most severe criminal sanction in the Act is s 64, which carries a maximum penalty of a fine of $24,000 or imprisonment for two years for knowingly making or providing false or misleading information in relation to an application or compliance with the Act.

Specific monetary penalties. Selected penalties include: failure to disclose a material personal interest by a Board member,$10,000 (s 25(1)); improper use of information by a member,$5,000 (s 32); failure to assist an inspector,individual $1,000, body corporate $2,500 (s 44(2)); owning a pharmacy business without premises registered,individual $5,000, body corporate $10,000 (s 53); unlawfully owning or holding proprietary interest,individual $5,000, body corporate $10,000 (s 54); exceeding ownership limits for new friendly societies,$50,000 (s 55(6) penalty); failure to appoint a pharmacist when required,$5,000 (s 56(2)); failure to give notice of appointment,$2,500 (s 56(3)); operating a pharmacy without a pharmacist appointed,individual $5,000, body corporate $10,000 (s 56(4)); failure to ensure personal supervision,individual $5,000, body corporate $10,000 (s 57); unauthorised non‑pharmacy businesses at registered premises,graduated fines for individuals and corporates (s 59). Use of the title “pharmacy” without entitlement carries fines of $2,500 for a first offence and $5,000 for subsequent offences (s 60).

Enforcement mechanisms and actors. The Board has a monitoring and enforcement function (s 8). It may enter and inspect registered pharmacies during business hours (s 44(1)) and request information under the application process (s 42(2)-(3)). The Board must follow procedural steps before cancelling or refusing renewal: give written notice with reasons and allow 14 days for representations (s 46(2)-(3)). The Board may impose, vary or revoke conditions on registration (s 47). Prosecutions for offences may be taken in the name of the Board by the registrar or authorised persons (s 70(1)). Offences are to be dealt with by a court of summary jurisdiction (magistrate) (s 70(2)).

Corporate officer liability. The Criminal Code provision on liability of officers (s 39) applies to specified offences listed in the Act via s 71; those sections include key corporate offences such as s 52 (notification of intended change in ownership), s 53 (carrying on pharmacy business at registered premises requirement), ss 54(1), 55(2) and (5) (ownership limits), ss 56(4), 57, 59 and 60 and s 64(1). Section 71 therefore imports the Criminal Code approach to officers’ criminal responsibility for offences by bodies corporate.

Administrative review and legal processes. Before imposing cancellation or conditions or refusing registration, the Board must provide reasons and follow the prescribed notice periods (s 67). Persons aggrieved by those decisions may apply to the State Administrative Tribunal for review (s 68). Proceedings for offences occur in the magistrates’ court (s 70). The Act also limits tort liability for persons acting in good faith under the Act (s 66), and protects publication of Board findings in good faith (s 69).

Discretion, transparency and parliamentary oversight. The Minister can direct the Board generally (s 11), but directions must be tabled in Parliament and recorded in the Board’s annual report (s 11(3)). The Board’s meetings are to be open to the public unless closed on specific grounds (s 33(1)-(2)); minutes are open for inspection subject to confidentiality and privacy (s 33(3)-(5)). These provisions create transparency obligations, but the Act also contains multiple discrete discretionary powers (impose conditions, refuse or grant registration despite standards, take action where public interest considered) that are subject to procedural safeguards.

Practical enforcement implications. The statutory architecture means that compliance is enforced through a mix of registration conditions, inspections, criminal sanctions for falsehoods and monetary penalties for specific breaches. The severe penalty in s 64 for false or misleading information increases legal risk around applications and statutory declarations supporting them (s 42(6)). Officers and directors of bodies corporate face specific exposure via s 71.

Cross‑referenced statutes and shared regulatory roles. The Act expressly relies on other statutes for key definitions and complementary regulation. It defines “pharmacist” by reference to the Health Practitioner Regulation National Law (WA) (s 3), so professional registration and conduct are governed by that National Law and the Pharmacy Board of Australia (National Board) (Part 9, defined terms). “Dispense” and the CEO referred to in s 51A are linked to the Medicines and Poisons Act 2014 (s 3 definition and s 51A). The Act excludes businesses operated by public hospitals as defined in the Health Services Act 2016 from the definition of pharmacy business (s 3). Corporations Act terminology is used for “officer” and corporate forms such as “company” and “director” (s 3).

Regulatory sequencing and data sharing. The Board must notify the CEO under the Medicines and Poisons Act of information recorded in the register as soon as practicable after it is recorded (s 51A). That creates an operational linkage between premises registration and medicines regulation, which may feed into licensing or permit decisions under the Medicines and Poisons Act.

Consistency with federal and national frameworks. The Act sits alongside the Health Practitioner Regulation National Law (WA) which governs pharmacist registration at the national level. The Act does not duplicate professional registration functions but imposes separate, property‑ and premises‑based requirements for owning and operating pharmacy businesses (s 3 definition of pharmacist and interplay in Part 9 transitional definitions). The Board and the National Board (Pharmacy Board of Australia) are different entities with different remits; the Act acknowledges the National Board and National Agency in transitional definitions (Part 9).

Impact on corporate law and duties. The Act’s definitions of “pharmacist controlled company” and the ownership rules in s 54 will affect corporate structuring and shareholding arrangements. The Act also imports the Criminal Code s 39 through s 71, thereby connecting corporate officer criminal liability under state criminal law to contraventions listed in the Table to s 71. Corporates holding pharmacy businesses must therefore reconcile compliance with this Act with director and officer duties under the Corporations Act and potential criminal exposure under the Criminal Code.

Interaction with taxation law and property registration. Transitional provisions include an exemption from state taxation for matters occurring by operation of the transitional Part (s 91). Section 92 directs relevant officials (Registrar of Titles, Registrar of Deeds etc.) to take notice and effect registration and recording of documents necessary to implement the transitional provisions. These sections show the Act’s interplay with revenue and land‑record regimes during transitions.

Rule‑making and regulatory hierarchy. The Act grants the Board rule‑making power (s 61) and the Governor regulatory power (s 62). Regulations prevail over inconsistent rules (s 62(3)). Rules require Governor confirmation (s 61(3)). That hierarchy is central to how minimum standards and fees will be developed and implemented, and means that the Board’s procedural rules ultimately operate within the framework the Governor and Executive establish via regulations.

Procedural law and review. Administrative review rights under the State Administrative Tribunal are provided by s 68; criminal proceedings are to be brought in a court of summary jurisdiction (s 70). The Act refers to the Interpretation Act 1984 for insolvency definitions and other interpretative rules (s 18(3) and s 77 note), tying into the broader statutory interpretative framework.

Transitional continuity with repealed Act and professional societies. Part 9 expressly carries over the former Council’s registers, certificates and agreements (ss 79, 83-86) and takes the unincorporated Pharmaceutical Society to be incorporated (s 88). Assets, liabilities and records transfer arrangements (s 89) interface with association law (Associations Incorporation Act) and corporate property law. The transitional provisions exempt certain transactions from state taxes (s 91) and direct registration authorities to record instruments (s 92).

The compilation table and marginal notes in the Act show a sequence of amendments and insertions since enactment.

Primary enactment and commencement. The Pharmacy Act 2010 (No. 32 of 2010) received assent on 26 August 2010 with ss 1-2 commencing that day and the balance commencing by proclamation on 18 October 2010 (compilation table).

Medicines and Poisons Act 2014 amendments. The Medicines and Poisons Act 2014 s 186 made amendments to the Pharmacy Act; the Act’s marginal notes record specific amendments to s 3 (definitions) and insertion of s 51A (requirement to notify the CEO of information recorded in the register), with the compilation showing those amendments commencing on 30 January 2017 (compilation table). The marginal note to s 3 records that s 3 was amended by No. 13 of 2014 s 186(2)-(4).

Associations Incorporation Act 2015 and Health Services Act 2016 references. The definitions and transitional arrangements reference the Associations Incorporation Act 2015 (s 225) and the Health Services Act 2016 (s 299). The compilation table records those amendment provisions and their commencement dates (1 July 2016 for the 2015 and 2016 Acts amendments).

Directors’ Liability Reform Act 2023. Section 71, which applies Criminal Code s 39 (liability of officers of bodies corporate) to a list of specified offences under the Pharmacy Act, was inserted by the Directors’ Liability Reform Act 2023 (Pt. 3 Div. 47), commenced 5 April 2023 (compilation table).

Statutes (Repeals and Minor Amendments) Act 2025. The compilation table records an amendment by the Statutes (Repeals and Minor Amendments) Act 2025 s 7, with assent 25 September 2025 and commencement 26 September 2025. The marginal note in the body of the Act indicates that s 58 was amended by No. 14 of 2025 s 7. Section 3 also carries amendment notes referencing the earlier amending Acts (No. 13 of 2014; No. 30 of 2015; No. 11 of 2016), which alter defined terms and relationships.

Transitional modifications and reprints. The Act includes Part 9 transitional provisions that preserve continuity with the repealed Pharmacy Act 1964 and make detailed transfer and saving provisions (ss 77-94). The Act has been reprinted (Reprint 1 as at 22 Sep 2017 was noted in the compilation table). The Notes to the Act record multiple amending Acts and the statutory sources of changes.

Practical implication of amendments in the Act text. The insertion of s 51A (2014 Medicines and Poisons Act) creates an explicit operational duty to notify the CEO of medicines and poisons matters recorded on the register. Section 71 (2023) imports Criminal Code officer liability to key pharmacy offences, increasing personal liability exposure for officers of corporate proprietors. The 2025 amendment to s 58 (as noted) affects transitional rules on death or bankruptcy of pharmacists, and the marginal note references indicate further definition changes across the years. The Act’s definitions table and marginal notes list the amended provisions and indicate the exact amending instruments and the parts of the Act altered.

This history is drawn only from the Act’s compilation table and marginal notes in the version supplied; users should consult the reprint and official consolidated text for operative versions and exact commencement dates of each amendment where timing is material to compliance.

The legislative text supplied does not record any judicial determinations or reported litigation under the Pharmacy Act 2010. The Act provides procedural mechanisms for challenging Board decisions and for criminal prosecution, but it does not list cases.

Statutory avenues for dispute resolution and review. The Act makes express provision for merits review: a person aggrieved by decisions listed in s 67(1) (refusal of registration, cancellation or non‑renewal, imposition or variation of conditions) may apply to the State Administrative Tribunal for review (s 68). The Tribunal is therefore the primary statutory venue for merits review of Board decisions concerning registration and conditions.

Criminal and summary jurisdiction. The Act states that proceedings for offences are to be taken in a court of summary jurisdiction constituted by a magistrate (s 70(2)). The Board may institute prosecutions in its own name through the registrar or an authorised person (s 70(1)). That structure anticipates criminal enforcement in the magistrates’ courts system rather than in higher courts for the summary offences provided.

Evidentiary presumptions and procedural points relevant to litigation. Section 70(4) provides evidentiary presumptions: certified copies or extracts from the register certified by the registrar are evidence of the facts appearing in them and the registrar’s appointment and signature are to be judicially noticed in the absence of contrary evidence (s 70(4)(a)-(b)). Section 71 imports the Criminal Code s 39 liability regime to certain offences, bringing with it established procedural and substantive law from the Criminal Code on corporate officer liability when cases are prosecuted.

No cases named in the Act. The Act itself does not cite judicial decisions or administrative appeals outcomes. Users seeking litigation history must search court and tribunal databases for decisions under the Pharmacy Act 2010, appeals to higher courts from decisions of the State Administrative Tribunal, or summary prosecutions in magistrates’ courts. This section therefore reports the statutory remedial and enforcement framework rather than any case law.

Narrow definitions that broaden through regulation. The statutory definitions of “proprietary interest” and “pharmacy business” are deliberately broad and expressly extended by regulation. Section 3(2) treats parties as holding proprietary interests where prescribed arrangements exist, or where a person provides a benefit entitling them to profits or income, or has a franchise or commercial arrangement entitling variable consideration. That means business or franchise arrangements which are not labelled as ownership but give profit‑linked returns can fall within the prohibition in s 54 if not structured to fit the permitted categories. The Act leaves some of the detail to regulations (s 62(2)(h)-(j) and s 62(2)(b)-(c)), so regulatory instruments will materially affect practical outcomes.

Supermarket prohibition and premises location traps. Sections 43(e) and 46(1)(e) require refusal or cancellation if the Board is satisfied the premises are located wholly or partly within, capable of being entered from, or capable of being used to gain entry to a supermarket. The statutory definition of “supermarket” is broad (s 3). That combination creates site selection constraints: premises that allow physical entry between the pharmacy and supermarket (even capability) can be refused or cancelled. Applicants and owners must design and document premises so they do not meet those criteria, as the Board’s satisfaction is the threshold.

Ownership limits and restructuring complexity. Section 55 limits pharmacists to ownership of interests in no more than four pharmacies and places similar limits on friendly societies and close family members. For corporates, the “pharmacist controlled company” definition (s 3) requires that at least one director is a pharmacist, every director is a pharmacist or a close family member of a pharmacist director, and that pharmacists control more than 50% of voting power. That can create complex governance and shareholding constraints. Transactions that alter control or shareholding may trigger notification obligations (s 52) and require prior structuring to remain within permitted bounds.

Notification timing and proof. Multiple time limits are strict and carry penalties. Intended acquisitions or disposals of proprietary interests require at least 14 days’ written advice to the registrar (s 52) or attract fines (s 52 penalty). Appointment of a pharmacist to have overall responsibility must be notified within seven days with evidence of agreement (s 56(3)), failure to do so attracts penalties. Applications must provide information and verification on oath where required (s 42(6)), and false or reckless statements attract the high criminal penalty in s 64.

Board discretion: “public interest” exception and conditions. The Board may register premises or continue registration despite non‑compliance with minimum standards where it is satisfied it is in the public interest and imposes conditions (s 48). That discretion can be used to preserve access in remote areas but exposes owners to stringent or onerous conditions (s 47). Practitioners should account for the possibility of conditional registrations and monitor compliance costs tied to conditions.

Ministerial involvement and information access. The Minister may give directions to the Board generally (s 11(1)), but cannot direct in relation to particular persons or matters (s 11(2)). The Minister may also request and copy Board information (s 12), although identity‑sensitive information is protected unless consent is given (s 12(5)). The Minister can declare ss 26 and 28 inapplicable (s 29), which can remove disqualification obligations for members with conflicts; parties should be alert to any ministerial declarations that affect Board composition for particular matters.

Rulemaking technicalities. The Board’s rules have no effect until confirmed by the Governor (s 61(3)). That means rules advertised by the Board have an interim state: they may not be in force until confirmation. By contrast, regulations made by the Governor (s 62) can have immediate effect and prevail over rules where inconsistent (s 62(3)). Practitioners need to track both rule and regulation instruments.

Register privacy and public access. The register is public (s 50) but may exclude private addresses without consent (s 50(5)). That creates a balance between transparency and privacy: proprietors should consider whether to give consent for publication of private addresses and understand what the public register will and will not show. The Board must notify the CEO of information recorded in the register (s 51A), which ties public listing to medicines and poisons regulation.

Criminal exposure for falsehoods. Section 64’s maximum penalty of $24,000 or two years’ imprisonment for false or misleading statements in applications and compliance documents creates a high legal risk. The Act therefore demands strong verification and careful legal review of statutory declarations, application materials and returns.

Corporate officer liability. Section 71 applies the Criminal Code officer liability provision to a suite of offences. Officers and directors of corporate proprietors should therefore assume possible personal liability arising from corporate contraventions and plan governance, compliance and indemnity structures accordingly.

Transitional arrangements and preserved entities. The preserved company (St John of God Health Care Incorporated) and friendly societies are given special statuses (s 3; ss 40-41; s 55). The preserved company cannot carry on pharmacy business at premises other than those at which it was carrying on business immediately before the repeal of the 1964 Act (s 41). Similar transitional provisions in Part 9 transfer assets and liabilities and create procedural quirks; practitioners dealing with historical arrangements should consult Part 9 carefully (ss 79-90).

Enforcement granularity. The Act provides many distinct offences with different penalties, some distinguish between individuals and corporations and some impose escalating penalties for repeat offences (eg s 59). Advisers must map conduct to the specific section to assess exposure.

Establish the correct ownership form. Before acquiring or structuring a pharmacy business, ensure the acquiring entity fits within s 54(1): pharmacist, partnership where partners are pharmacists or close family members, pharmacist controlled company, friendly society, or the preserved company. If a company is used, ensure the “pharmacist controlled company” tests are met: at least one director is a pharmacist, every director is either a pharmacist or a close family member of a pharmacist director, and pharmacists have control of more than 50% of voting power (s 3 definition). If the intended structure is a friendly society, check whether it is a “new friendly society” and whether s 55(5) caps apply.

Plan acquisition timing and notifications. Provide the registrar written notice at least 14 days before any intended acquisition or disposal of ownership or proprietary interest (s 52). Factor this into transaction timetables and due diligence. Because the content of “proprietary interest” is broadened by s 3(2), include a review of any profit‑sharing, franchise or other commercial arrangements that might be captured.

Comply with premises registration and application requirements. Apply under s 42 in the approved form, pay the prescribed fee and attach the information required by regulation. Be ready to respond to Board requests for further information or attendance to satisfy premises fitness (s 42(2)-(4)). Verify information by statutory declaration if required (s 42(6)). Because false or misleading statements carry high penalties (s 64) ensure accuracy and legal review of declarations and supporting documents.

Meet minimum standards and prepare for inspections. The regulations will prescribe minimum standards of fitness for premises (s 62(2)(a)). Ensure premises meet those standards before applying; the Board may refuse under s 43(a) or cancel under s 46(1)(a) if standards are not met. The Board may inspect registered pharmacies during business hours (s 44(1)); ensure staff are trained to provide reasonable assistance and maintain documentation to demonstrate compliance (s 44(2)).

Appoint and notify a pharmacist with overall responsibility. If the registered owner is not a pharmacist, appoint a pharmacist to have overall responsibility and notify the Board within seven days with name, address, commencement date and evidence of agreement (s 56(2)-(3)). Ensure that a pharmacist is present for personal supervision at all times as required by s 57 and that rosters and staff arrangements support that obligation.

Manage conditions and regulatory changes. Expect possible conditions on registration (s 47) and maintain systems to comply with any conditions imposed. Monitor rulemaking and regulation instruments: Board rules need Governor confirmation (s 61(3)) and regulations may override rules (s 62(3)); keep updated copies of both.

Keep accurate register data and inform medicines regulators. Ensure the register entry is accurate and that the Board is notified of changes; the Board must notify the Medicines and Poisons CEO of recorded register information (s 51A). If you withhold private address consent, be aware of the limits on public disclosure (s 50(5)).

Maintain corporate governance and officer awareness. Because s 71 imports Criminal Code officer liability, ensure directors and officers understand the statutory offences listed and the potential for personal liability. Put in place compliance policies, regular reporting, and legal oversight of statutory returns and notifications to the Board.

Avoid disallowed locations and mixed uses. Do not locate a pharmacy wholly or partly within a supermarket or in premises capable of being entered from or used to gain entry to a supermarket unless the Board allows it (ss 43(e), 46(1)(e)). For non‑pharmacy activities at registered premises, ensure the party carrying on the business is permitted by s 59 (registered proprietor, pharmacist partner or pharmacist director of same pharmacist controlled company).

Prepare for Board interaction and review rights. If the Board proposes to cancel or refuse renewal, submit written representations within 14 days as required by s 46(3). If aggrieved by decisions recorded under s 67(1), apply to the State Administrative Tribunal for review (s 68). Keep records of notices and decisions; the Board must provide reasons and grounds within 30 days (s 67(2)).

Document everything and use statutory declarations where required. The Act demands verified information at stages (s 42(6)): use statutory declarations responsibly and under legal guidance. Given the severe penalty for false or misleading information (s 64), ensure that legal advisors vet application materials, statutory declarations and renewal filings.

Budget for fees, audits and reporting. The Board’s funds come from fees (s 35) and the Board may prescribe fees by rule (s 61(2)). Maintain adequate financial records and prepare audited financial statements annually under Australian Accounting Standards (ss 36-37) where applicable to the Board or to entities subject to Board fees or reporting.

Monitor rule and regulation developments. Because many operational details (minimum standards, permitted associated goods and services, fees, forms) are left to regulations (s 62) and rules (s 61), subscribe to the Board’s publications, the Gazette, and regulatory trackers. The Board must include its rules and directions in its annual report (s 38(1), s 11(3)).

Train staff and document supervision. Train pharmacists and staff on duties relating to personal supervision, pharmacy practice scope and assisting inspectors. Maintain rosters proving that a pharmacist is on site and that the pharmacist with overall responsibility has oversight. Documentation will be critical in case of inspections, cancellations or prosecutions.

Seek legal advice for complex arrangements. Given the breadth of “proprietary interest” and the possibility of personal criminal liability for officers (s 71), obtain legal advice for franchise agreements, profit‑sharing arrangements, cross‑shareholdings and family trusts to ensure they do not unintentionally confer proprietary interests contrary to s 54 and s 55.

Finally, for transitions and historical transfers, follow Part 9 carefully. If you are an affected institution (former Council, preserved company or the unincorporated Pharmaceutical Society), Part 9 contains specific steps on transfers of assets, certificates, incorporation and exemptions from State taxes (ss 79-93).